{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:44:17Z","timestamp":1793681057150,"version":"4.5.1"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":9504,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1987,3]]},"abstract":"<jats:p><jats:italic>The aim of these two studies was to evaluate the safety and pharmacokinetics of oral nalmefene, a new orally effective opioid antagonist. In the first study, single ascending doses of 50, 100, 200, and 300 mg of nalmefene HCl were administered in double\u2010blind fashion to four groups of healthy men. There were six subjects in each group; four received nalmefene and two received placebo. The drug was well tolerated at all dose levels with only mild and transient side effects, such as lightheadedness, at the higher doses. Model\u2010independent pharmacokinetic analysis of the plasma concentration\u2010time dathowed that nalmefene was rapidly absorbed and had an elimination half\u2010life that ranged from seven to 15 hours (mean, 10.7 hr). There was a good linear relationship (<\/jats:italic>r =<jats:italic>.97) between administered dose and total area under the curve at each dose level. Only about 4% of the dose was excreted in the urine as unchanged nalmefene, whereas up to 60% was excreted as a \u03b2\u2010glucuronidase\/sulfatase hydrolysable conjugate(s) of nalmefene. In the second study, six healthy men were initially administered a single 50\u2010mg dose of drug, and plasma samples were obtained at selected time intervals for 48 hours. A dosing schedule of 20 mg q12h was then started and continued for seven days. Plasma samples were collected immediately before each dose and at selected times for up to 48 hours after the last dose. The drug was well tolerated by all subjects, and no clinically significant adverse effects were observed during the seven\u2010day administration period. In most instances, the steady\u2010state plasma concentrations could be reasonably predicated from the single dose data and had a moderate accumulation factor (about 1.6). There was no significant difference in the mean half\u2010life following the first and last dose. Both studies indicate that orally administered nalmefene has a wide margin of safety in healthy men and exhibits a linear pharmacokinetic profile at the doses tested<\/jats:italic>.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1987.tb02191.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T23:52:26Z","timestamp":1362786746000},"page":"233-239","source":"Crossref","is-referenced-by-count":72,"title":["Nalmefene: Safety and Kinetics After Single and Multiple Oral Doses of a New Opioid Antagonist"],"prefix":"10.1002","volume":"27","author":[{"given":"Ross","family":"Dixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hon\u2010Bin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyal","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Weidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"175","article-title":"Binding of a new opiate antagonist, nalmefene, to rat brain membranes","volume":"7","author":"Michel ME","year":"1985","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00237a008"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.9"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600731141"},{"key":"e_1_2_1_6_2","first-page":"449","article-title":"Nalmefene: Quantitation of a new narcotic antagonist in human plasma using HPLC with electrochemical detection","volume":"42","author":"Hsiao J","year":"1983","journal-title":"Res Comm Chem Pathol Pharmacol"},{"key":"e_1_2_1_7_2","first-page":"179","article-title":"Model\u2010independent linear pharmacokinetics","volume":"10","author":"Wagner J","year":"1976","journal-title":"Drug Intell Clin Pharm"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198409001-00381"},{"key":"e_1_2_1_9_2","first-page":"15","article-title":"Bioequivalence, dose proportionality and pharmacokinetics of naltrexone after oral administration","volume":"45","author":"Meyer MC","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.220"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600710139"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0090-9556(25)06161-6","article-title":"Metabolism and disposition of naltrexone in man after oral and intravenous administration","volume":"9","author":"Wall ME","year":"1981","journal-title":"Drug Metab Dispos"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1987.tb02191.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1987.tb02191.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:40:08Z","timestamp":1745970008000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1987.tb02191.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1987,3]]}},"alternative-id":["10.1002\/j.1552-4604.1987.tb02191.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1987.tb02191.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,3]]}}}